PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

Nature Medicine

Volumn 20, Issue 7, 2014, Pages 741-747

  Bajou, Khalid ^a   Herkenne, Stephanie ^a   Thijssen, Victor L ^b   D'Amico, Salvino ^a   Nguyen, Ngoc Quynh Nhu ^a   Bouché, Ann ^c,d   Tabruyn, Sébastien ^a   Srahna, Mohammed ^a   Carabin, Jean Yves ^a   Nivelles, Olivier ^a   Paques, Cécile ^a   Cornelissen, Ivo ^c,d   Lion, Michelle ^a   Noel, Agnès ^a   Gils, Ann ^e   Vinckier, Stefan ^c,d   Declerck, Paul J ^e   Griffioen, Arjan W ^b   Dewerchin, Mieke ^c,d   Martial, Joseph A ^a   Carmeliet, Peter ^c,d   Struman, Ingrid ^a   more..

^a UNIVERSITY OF LIÈGE   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

16K PROLACTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLACTIN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CLOT LYSIS; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL LINE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TUMOR GROWTH; TUMOR MODEL; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS;

ANIMALS; CELL DIVISION; CELLS, CULTURED; FIBRINOLYSIS; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLACTIN;

EID: 84904053460     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3552     Document Type: Article

References (56)

1. Chung, A.S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10, 505-514 (2010).
2. Struman, I. et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA 96, 1246-1251 (1999).
3. Clapp, C., Aranda, J., Gonzalez, C., Jeziorski, M.C. & Martinez de la Escalera, G. Vasoinhibins: endogenous regulators of angiogenesis and vascular function. Trends Endocrinol. Metab. 17, 301-307 (2006).
4. Bentzien, F., Struman, I., Martini, J.F., Martial, J. & Weiner, R. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1-/- mice. Cancer Res. 61, 7356-7362 (2001).
5. Kim, J. et al. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res. 63, 386-393 (2003).
6. Kinet, V. et al. Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer Lett. 284, 222-228 (2009).
7. Nguyen, N.Q. et al. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Mol. Ther. 15, 2094-2100 (2007).
8. Tabruyn, S.P. et al. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-κB activation. Mol. Endocrinol. 21, 1422-1429 (2007).
9. Nguyen, N.Q. et al. The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation. PLo S ONE 6, e27318 (2011).
10. García, C. et al. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J. Clin. Invest. 118, 2291-2300 (2008).
11. González, C. et al. Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Lab. Invest. 87, 1009-1017 (2007).
12. Hilfiker-Kleiner, D. et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128, 589-600 (2007).
13. Halkein, J. et al. Micro RNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J. Clin. Invest. 123, 2143-2154 (2013).
14. Tabruyn, S.P., Nguyen, N.Q., Cornet, A.M., Martial, J.A. & Struman, I. The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol. Endocrinol. 19, 1932-1942 (2005).
15. D'Angelo, G. et al. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol. Endocrinol. 13, 692-704 (1999).
16. D'Angelo, G., Struman, I., Martial, J. & Weiner, R.I. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. USA 92, 6374-6378 (1995).
17. Tabruyn, S.P. et al. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-κB. Mol. Endocrinol. 17, 1815-1823 (2003).
18. Clapp, C. & Weiner, R.I. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 130, 1380-1386 (1992).
19. Rijken, D.C., Wijngaards, G. & Welbergen, J. Immunological characterization of plasminogen activator activities in human tissues and body fluids. J. Lab. Clin. Med. 97, 477-486 (1981).
20. Eitzman, D.T., Krauss, J.C., Shen, T., Cui, J. & Ginsburg Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87, 4718-4722 (1996).
21. Carmeliet, P. et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 96, 3180-3191 (1997).
22. Bajou, K. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4, 923-928 (1998).
23. Bajou, K. et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol. 152, 777-784 (2001).
24. Bajou, K. et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23, 6986-6990 (2004).
25. Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163-1177 (2003).
26. Mc Mahon, G.A. et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 276, 33964-33968 (2001).
27. Binder, B.R., Mihaly, J. & Prager, G.W. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb. Haemost. 97, 336-342 (2007).
28. Conese, M. et al. α-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J. Cell Biol. 131, 1609-1622 (1995).
29. Lee, S.H., Kunz, J., Lin, S.H. & Yu-Lee, L.Y. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res. 67, 11045-11053 (2007).
30. Martini, J.F. et al. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol. Endocrinol. 14, 1536-1549 (2000).
31. Declerck, P.J. et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J. Biol. Chem. 263, 15454-15461 (1988).
32. Seiffert, D. & Loskutoff, D.J. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J. Biol. Chem. 266, 2824-2830 (1991).
33. Mutch, N.J., Thomas, L., Moore, N.R., Lisiak, K.M. & Booth, N.A. TAFIa, PAI-1 and α-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J. Thromb. Haemost. 5, 812-817 (2007).
34. Zhu, Y., Carmeliet, P. & Fay, W.P. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 99, 3050-3055 (1999).
35. Shu, E., Matsuno, H., Ishisaki, A., Kitajima, Y. & Kozawa, O. Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice. Pathophysiol. Haemost. Thromb. 33, 206-213 (2003).
36. Blasi, F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15, 105-111 (1993).
37. Prager, G.W. et al. Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. Blood 113, 1383-1390 (2009).
38. La Rusch, G.A. et al. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. Blood 115, 5111-5120 (2010).
39. Smith, L.H. et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 107, 132-134 (2006).
40. Tsantes, A.E. et al. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb. Res. 122, 736-742 (2008).
41. Nalluri, S.R., Chu, D., Keresztes, R., Zhu, X. & Wu, S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. J. Am. Med. Assoc. 300, 2277-2285 (2008).
42. Scappaticci, F.A. et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl. Cancer Inst. 99, 1232-1239 (2007).
43. Zangari, M. et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J. Clin. Oncol. 27, 4865-4873 (2009).
44. Nar, H. et al. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J. Mol. Biol. 297, 683-695 (2000).
45. Gils, A., Knockaert, I. & Declerck, P.J. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 35, 7474-7481 (1996).
46. Thijssen, V.L. et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. USA 103, 15975-15980 (2006).
47. Jaffe, E.A., Nachman, R.L., Becker, C.G. & Minick, C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52, 2745-2756 (1973).
48. Fusenig, N.E., Amer, S.M., Boukamp, P. & Worst, P.K. Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo. Bull. Cancer 65, 271-279 (1978).
49. Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt) Method. Methods 25, 402-408 (2001).
50. Sabatel, C. et al. Micro RNA-21 exhibits antiangiogenic function by targeting Rho B expression in endothelial cells. PLo S ONE 6, e16979 (2011).
51. Ngo, T.H., Debrock, S. & Declerck, P.J. Identification of functional synergism between monoclonal antibodies. Application to the enhancement of plasminogen activator inhibitor-1 neutralizing effects. FEBS Lett. 416, 373-376 (1997).
52. Carmeliet, P. et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J. Clin. Invest. 92, 2746-2755 (1993).
53. Bajou, K. et al. Plasminogen activator inhibitor-1 protects endothelial cells from Fas L-mediated apoptosis. Cancer Cell 14, 324-334 (2008).
54. Carmeliet, P. et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368, 419-424 (1994).
55. Passaniti, A. et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67, 519-528 (1992).
56. Vercauteren, E. et al. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. Blood 117, 4615-4622 (2011).